BMS 986089

Drug Profile

BMS 986089

Alternative Names: Anti-myostatin adnectin; BMS-986089; Myostatin-inhibiting adnectin fusion protein; RG 6206

Latest Information Update: 04 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Adnexus Therapeutics
  • Developer Bristol-Myers Squibb; Roche
  • Class Proteins
  • Mechanism of Action Myostatin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Duchenne muscular dystrophy

Most Recent Events

  • 09 Jun 2017 Phase-II/III clinical trials in Duchenne muscular dystrophy (In children) in USA (SC) (NCT03039686)
  • 09 May 2017 Bristol-Myers Squibb initiates enrolment in a phase I trial in Healthy volunteers in USA (NCT03100630)
  • 13 Apr 2017 BMS 986089 licensed to Roche for the treatment of Duchenne muscular dystrophy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top